According to President Trump, “Tariff is the most beautiful word in the dictionary.” Throughout his presidential campaign, Trump promised to use tariffs as a central part of his foreign policy strategy. His America First Trade Policy memorandum also directs the administration to review various tariff- and tariff-adjacent levers the United States could use to further
Nonprofit Resources of the Week – 5/2/26
Nonprofit Resources of the Week curates timely articles, tools, and commentary to help nonprofit organizations, their leaders, and their advisors stay informed about legal developments, sector trends, and emerging issues affecting the nonprofit and philanthropic ecosystem, including those related to equity, climate change, and resilience. The series also seeks to share tools, perspectives, and sources
The End of Keywords? Travel Marketing Faces an AI Reset
Good Saturday morning from San Diego . . . Our weekly Online Travel Update for the week ending Friday, May 1, 2026, is below. As the number of stories included in our weekly Update indicate, it was a busy week in online travel with Booking Holdings’ quarterly earnings release (a complete copy of the earnings
Google betting $40B on Anthropic in AI Race!
BankInfoSecurity.com reported that “Google plans to deepen its ties with Anthropic through an initial $10 billion investment and up to $30 billion more tied to performance milestones.” The April 28, 2026 article entitled ” Google Bets Up to $40B on Anthropic as AI Compute Race Grows” (https://www.bankinfosecurity.com/google-bets-up-to-40b-on-anthropic-as-ai-compute-race-grows-a-31533?rf=2026-04-29_ENEWS_SUB_BIS__Slot1_ART31533&mkt_tok=MDUxLVpYSS0yMzcAAAGheKzE0ypMpISk2B6jUVmKg84V0eWFo6icnRfTX2MkVmppl4oeKwEvgmtx8CasIcZu_FHR2zatxyWAHZM_HVIK1CjNXroWxu4kX-AdTOFTFS437ZLVBA) included these comments:
The deal expands
AI Bill Passes General Assembly; Broad Workforce Bill Follows
Earlier today, the General Assembly gave final approval to two significant workplace bills that employers now need to focus on.
In this post, I’ll cover
The Provocative Abramowitz Keynote And The Computer That Won’t Come On
Here’s my Above the Law post on Zach Abramowitz’s keynote at ILTA’s Evolve conferance. The keynote lived up to its title: Most Law Firms Are Doing AI Wrong. Here’s How to Do It Right.
His argument is that the failures in GenAI adoption from ineffective training to analysis paralysis to hallucination panic, all trace back
California Legislature Proposes 90-Day Layoff Notice Requirement Due to Employer’s AI Use
Quick Hits
- California Senate Bill 951 would require employers to provide at least ninety days’ advance written notice before eliminating positions due to AI or automation affecting twenty-five or more workers or twenty-five percent of the workforce, and to separately notify state agencies when they permanently stop hiring for roles replaced by AI.
- The bill
What Makes a Violin Unique and Why AI Can’t (Yet) Replace Humans In Contract Preparation
Violins made by Antonio Stradivari (called “Strads”) in the late-Seventeenth and early-Eighteenth centuries are widely considered the best ever made. Yet for more than three centuries, musicians, collectors, scientists, and instrument makers (luthiers) have tried to determine why Strads stand in a class of their own.There are many theories why Strads are unique. Maybe the
The Colorado AI Act Hits a Wall: Litigation, Legislative Uncertainty, and an Enforcement Standstill
The Colorado AI Act (SB24-205) is effectively frozen just weeks before its June 30, 2026 effective date, following a stay in enforcement of the law by a Magistrate Judge in the District of Colorado on April 27, 2026.
Background
By way of background, on April 9, xAI filed suit in federal court seeking to enjoin
AbbVie Regulatory Submission and Deal News
AbbVie Submits Regulatory Application to FDA for Subcutaneous SKYRIZI
On April 27, 2026, AbbVie announced that it has submitted a regulatory application to the FDA seeking approval for SKYRIZI (risankizumab-rzaa) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. AbbVie states that its application is supported by positive data